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PRESENTATION
A 64-year-old man with myasthenia gravis (MG)
presented with blurry vision in his left eye (OS).
His visual acuity was 20/20 in the right eye
and 20/50 OS. His intraocular pressures, pupils,
and anterior segment were normal. He had 1+
vitritis and vaso-occlusive appearance of the
retina with sclerotic vessels and hemorrhages
in the inferonasal quadrant OS (Figure 1),
consistent with features of cytomegalovirus
(CMV) retinitis. He was immunocompromised
secondary to mycophenolate mofetil (MMF)
administered for MG, with 0.6% lymphocytes
(normal: 26.0–46.0%), a lymphocyte count of
0.1×103 cells/μL, and a leukocyte count of 11.3×103
cells/μL. He was receiving 1000 mg of MMF
BID. The human immunodeficiency virus (HIV)
test result was negative, and no further workup
for immunosuppression, including cancer, was
conducted.
The patient was administered with 0.05 mL
ganciclovir (4 mg/0.1 mL) and 0.10 mL foscarnet
(2.4 mg/0.1 mL) intravitreal injections on diagnosis.
Subsequently, his symptoms improved, and
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a 10-week course of oral valganciclovir (900
mg BID for 21 days followed by 900 mg QD
for seven weeks) was administered. There was
also a decrease in the dosage and eventual
cessation of MMF with initiation of intravenous
immunoglobulins. His lymphocytes improved
to 9.8% (lymphocyte count, 0.7×103 cells/μL;
leukocyte count, 6.9×103 cells/μL).
On valganciclovir discontinuation in week 10,
the patient had a visual acuity of 20/25 OS
with no inflammation and improvements in retinal
hemorrhages and lesions. An epiretinal membrane
was observed on macular optical coherence
tomography (Figure 2). The inferonasal retina
showed inactive whitish atrophy (Figure 3).
DISCUSSION
CMV retinitis is the most common ocular
opportunistic infection associated with acquired
immune deficiency syndrome.[1] The prevalence of
CMV retinitis in HIV patients has decreased since
the advent of highly active antiretroviral therapy
(HAART).[2] However, the rate of CMV retinitis in
non-HIV patients is increasing, likely due to the use
of aggressive immunosuppressive agents.[1] CMV
is an infectious complication frequently associated
with MMF.[3]
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Figure 1. (A) A funduscopic photo of the left eye shows fluffy white lesions with intraretinal hemorrhage predominantly in the
inferonasal quadrant. (B) A funduscopic photo of the left inferonasal quadrant five weeks after treatment initiation.
Figure 2. (A) OCT of the macula of the left eye before treatment initiation showing vitreomacular adhesion and few vitreous cells.
(B) OCT of the macula of the left eye after 10 weeks from treatment initiation showing a fine epiretinal membrane.
Visual prognosis of CMV infection in non-
HIV patients is similar to that in HIV patients
with poor visual outcomes associated with
retinal detachments and macular involvement.[1]
CMV retinitis in patients with concomitant
HIV infection lacks vitreous involvement.[2]
In contrast, vitritis is more commonly
associated with non-HIV-related CMV retinitis
infections.[2] This is consistent with our patient’s
presentation.
CMV retinitis treatment in HIV patients
involves HAART and antiviral therapy.[1] In
non-HIV patients, different etiologies of an
immunocompromised state must be considered.
Commonly used treatment strategies include
systemic ganciclovir, foscarnet, valganciclovir,
and intravitreal ganciclovir. Our patient received
one initial intravitreal injection each of ganciclovir
and foscarnet, as well as oral valganciclovir.
Intravitreal injections are important for the
treatment of vision-threatening CMV infections
and were used in our case.[4] Nevertheless, the
mainstay treatment of CMV retinitis remains
systemic antivirals, and it is not always
necessary to start with intravitreal injections.
The combination of intravitreal ganciclovir
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Figure 3. The inferonasal fundus photo of the left eye at 10 weeks showing preretinal fibrosis with a corresponding OCT (over
the white lesion, see Arrow) showing an atrophic retina with resolved vitritis. A corresponding infrared image showing the line of
scan of the OCT.
and foscarnet is effective in treating CMV
retinitis.[5]
In summary, we presented a patient with
MG who developed CMV retinitis due to
immunosuppression as a result of MMF treatment.
He was treated successfully with intravitreal
and systemic antivirals.
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